Insuficiencia hepática fulminante

Fulminant hepatic failure (FHF) is an acute and eventually fatal illness, caused by a severe hepatocyte damage with massive necrosis. Its hallmarks are hepatic encephalopathy and a prolonged prothrombin time (<40%). FHF is currently defined as hyperacute (encephalopathy appearing within 7 days of...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Poniachik T,Jaime, Quera P,Rodrigo, Lui G,Andrea
Lenguaje:	Spanish / Castilian
Publicado:	Sociedad Médica de Santiago 2002
Materias:	Hepatic encephalopathy Hepatic failure, fulminant Hypoprothrombinemia Liver transplantation Prothrombin
Acceso en línea:	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872002000600014
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:scielo:S0034-98872002000600014
record_format	dspace
spelling	oai:scielo:S0034-988720020006000142014-08-20Insuficiencia hepática fulminantePoniachik T,JaimeQuera P,RodrigoLui G,Andrea Hepatic encephalopathy Hepatic failure, fulminant Hypoprothrombinemia Liver transplantation Prothrombin Fulminant hepatic failure (FHF) is an acute and eventually fatal illness, caused by a severe hepatocyte damage with massive necrosis. Its hallmarks are hepatic encephalopathy and a prolonged prothrombin time (<40%). FHF is currently defined as hyperacute (encephalopathy appearing within 7 days of the onset of jaundice), acute (encephalopathy appearing between 8 and 28 days) or subacute (encephalopathy appearing between 5 and 12 weeks). FHF can be caused by viruses, drugs, toxins, and miscellaneous conditions such as Wilsons disease, Budd-Chiari syndrome, ischemia and others. However, a single most common etiology is still not defined. Factors that are valuable in assessing the likelihood of spontaneous recovery are age, etiology, degree of encephalopathy, prothrombin time and serum bilirubin. The management is based in the early treatment of infections, hemodynamic abnormalities, cerebral edema, and other associated conditions. Liver transplant has emerged as the most important advance in the therapy of FHF, with a survival rate that ranges between 60 and 80%. The use of hepatic support systems, extracorporeal liver support and auxiliary liver transplantation are innovative therapies (Rev Méd Chile 2002; 130: 691-698).info:eu-repo/semantics/openAccessSociedad Médica de SantiagoRevista médica de Chile v.130 n.6 20022002-06-01text/htmlhttp://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872002000600014es10.4067/S0034-98872002000600014
institution	Scielo Chile
collection	Scielo Chile
language	Spanish / Castilian
topic	Hepatic encephalopathy Hepatic failure, fulminant Hypoprothrombinemia Liver transplantation Prothrombin
spellingShingle	Hepatic encephalopathy Hepatic failure, fulminant Hypoprothrombinemia Liver transplantation Prothrombin Poniachik T,Jaime Quera P,Rodrigo Lui G,Andrea Insuficiencia hepática fulminante
description	Fulminant hepatic failure (FHF) is an acute and eventually fatal illness, caused by a severe hepatocyte damage with massive necrosis. Its hallmarks are hepatic encephalopathy and a prolonged prothrombin time (<40%). FHF is currently defined as hyperacute (encephalopathy appearing within 7 days of the onset of jaundice), acute (encephalopathy appearing between 8 and 28 days) or subacute (encephalopathy appearing between 5 and 12 weeks). FHF can be caused by viruses, drugs, toxins, and miscellaneous conditions such as Wilsons disease, Budd-Chiari syndrome, ischemia and others. However, a single most common etiology is still not defined. Factors that are valuable in assessing the likelihood of spontaneous recovery are age, etiology, degree of encephalopathy, prothrombin time and serum bilirubin. The management is based in the early treatment of infections, hemodynamic abnormalities, cerebral edema, and other associated conditions. Liver transplant has emerged as the most important advance in the therapy of FHF, with a survival rate that ranges between 60 and 80%. The use of hepatic support systems, extracorporeal liver support and auxiliary liver transplantation are innovative therapies (Rev Méd Chile 2002; 130: 691-698).
author	Poniachik T,Jaime Quera P,Rodrigo Lui G,Andrea
author_facet	Poniachik T,Jaime Quera P,Rodrigo Lui G,Andrea
author_sort	Poniachik T,Jaime
title	Insuficiencia hepática fulminante
title_short	Insuficiencia hepática fulminante
title_full	Insuficiencia hepática fulminante
title_fullStr	Insuficiencia hepática fulminante
title_full_unstemmed	Insuficiencia hepática fulminante
title_sort	insuficiencia hepática fulminante
publisher	Sociedad Médica de Santiago
publishDate	2002
url	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872002000600014
work_keys_str_mv	AT poniachiktjaime insuficienciahepaticafulminante AT queraprodrigo insuficienciahepaticafulminante AT luigandrea insuficienciahepaticafulminante
_version_	1718436039201128448

Insuficiencia hepática fulminante

Ejemplares similares